NASDAQ · RDNT
Healthcare · Medical - Diagnostics & Research
$74.28
Up+$3.41 (+4.81%)
Updated Sep 11, 2026, 8:13 AM
SID Score
5.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RDNT closed at $74.28 after 20 trading sessions, down 3.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $70.45 | $75.10 | $70.45 | $74.28 | 801.88K |
| Sep 9, 2026 | $71.31 | $72.555 | $70.08 | $70.87 | 575.14K |
| Sep 8, 2026 | $72.72 | $73.53 | $71.82 | $71.97 | 455.28K |
| Sep 4, 2026 | $73.82 | $74.70 | $73.36 | $73.71 | 502.02K |
| Sep 3, 2026 | $76.22 | $76.27 | $73.265 | $74.62 | 1.14M |
| Sep 2, 2026 | $75.41 | $76.97 | $75.31 | $75.70 | 712.85K |
| Sep 1, 2026 | $75.80 | $76.63 | $74.8125 | $75.52 | 762.97K |
| Aug 31, 2026 | $75.245 | $76.30 | $73.50 | $75.82 | 658.12K |
| Aug 28, 2026 | $75.72 | $75.86 | $74.115 | $74.61 | 472.84K |
| Aug 27, 2026 | $75.75 | $76.50 | $74.94 | $75.36 | 528.47K |
| Aug 26, 2026 | $76.96 | $77.7899 | $75.29 | $76.47 | 391.3K |
| Aug 25, 2026 | $75.52 | $77.09 | $73.81 | $76.86 | 444.93K |
| Aug 24, 2026 | $76.98 | $77.50 | $74.01 | $74.69 | 549.48K |
| Aug 21, 2026 | $76.96 | $78.285 | $75.86 | $76.82 | 644.95K |
| Aug 20, 2026 | $74.64 | $78.02 | $74.64 | $77.05 | 479.69K |
| Aug 19, 2026 | $75.07 | $76.56 | $74.615 | $75.54 | 371.91K |
| Aug 18, 2026 | $75.79 | $76.4534 | $73.73 | $73.83 | 548.62K |
| Aug 17, 2026 | $76.17 | $76.66 | $75.00 | $75.93 | 596.24K |
| Aug 14, 2026 | $76.87 | $78.1421 | $75.84 | $76.35 | 632.88K |
| Aug 13, 2026 | $77.00 | $78.16 | $76.44 | $77.31 | 663.41K |
The latest Smart Investors Daily articles mentioning RDNT.
RDNT research
Company profile and research snapshot.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Barclays | Overweight | — |
| Aug 11, 2026 | Truist Securities | Buy | — |
| May 20, 2026 | Barclays | Overweight | — |
| Apr 21, 2026 | Barclays | Overweight | — |
| Jan 9, 2026 | Keybanc | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 4, 2026
On August 9, RadNet (NASDAQ:RDNT) posted second-quarter revenue of $622.7 million, a 25.0% jump from $498.2 million a year earlier, and raised its full-year outlook for the second time in three months. The imaging network also grew profit at a slower clip than sales, and a six-month net loss widened even as the headline numbers […]
Benzinga · Aug 28, 2026
Barclays analyst Andrew Mok maintains RadNet (NASDAQ:RDNT) with a Overweight and raises the price target from $65 to $79.
Yahoo · Aug 26, 2026
The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare IT within an end-to-end platform spanning scan, analysis and interpretation. Nanox is expanding its commercial reach th...
SeekingAlpha · Aug 12, 2026
RadNet's joint ventures across healthcare systems also help it deepen its integration across customers' workflows. Read why RDNT stock is a Strong Buy.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RDNT.
